Physician profile
Richard Powers
NPI 1467428680
$3,479.80
in general payments reported to CMS, 2019-2025
43 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $304 · 2021: $549 · 2022: $632 · 2023: $611 · 2024: $571 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $401.56 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $387.93 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $299.25 | 2019-2025 | |
| Lilly USA, LLC | $253.60 | 2019-2025 | Mounjaro, Jardiance |
| Dexcom, INC. | $231.43 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.57 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $129.90 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $129.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $116.62 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Esperion Therapeutics, INC. | $113.89 | 2020-2024 | Nexletol |
| Corcept Therapeutics | $110.06 | 2025 | Korlym |
| Boston Scientific Corporation | $109.84 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $90.94 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $88.62 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.